CRISPR Therapeutics’ (CRSP) “Neutral” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research note issued to investors on Thursday morning, Benzinga reports.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC lowered their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a buy rating on the stock in a report on Tuesday. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They issued a buy rating and a $90.00 price target on the stock. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a buy rating on the stock in a report on Tuesday. JMP Securities reaffirmed a market outperform rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Finally, Barclays lowered their price target on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an equal weight rating on the stock in a report on Tuesday. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, CRISPR Therapeutics has a consensus rating of Hold and an average target price of $74.00.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP traded down $0.85 during midday trading on Thursday, reaching $47.01. The company’s stock had a trading volume of 998,453 shares, compared to its average volume of 1,596,176. CRISPR Therapeutics has a 12-month low of $37.55 and a 12-month high of $91.10. The firm has a 50 day moving average price of $56.72 and a 200-day moving average price of $62.88. The stock has a market capitalization of $3.99 billion, a P/E ratio of -17.28 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06). The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. The firm’s revenue was down 99.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.98) EPS. On average, equities analysts predict that CRISPR Therapeutics will post -5.52 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at $378,327.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Global Trust Asset Management LLC boosted its position in CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after buying an additional 300 shares during the period. Larson Financial Group LLC boosted its position in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares during the period. GPS Wealth Strategies Group LLC boosted its position in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after buying an additional 307 shares during the period. Bourgeon Capital Management LLC boosted its position in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after buying an additional 500 shares during the period. Finally, Riggs Asset Managment Co. Inc. boosted its position in CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after buying an additional 200 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.